Search Results - "Schram, Alison M"

How I treat hemophagocytic lymphohistiocytosis in the adult patient by Schram, Alison M., Berliner, Nancy

“…Hemophagocytic lymphohistiocytosis (HLH) is a devastating disorder of uncontrolled immune activation characterized by clinical and laboratory evidence of…”
Get full text

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions by Cocco, Emiliano, Benhamida, Jamal, Middha, Sumit, Zehir, Ahmet, Mullaney, Kerry, Shia, Jinru, Yaeger, Rona, Zhang, Liying, Wong, Donna, Villafania, Liliana, Nafa, Khedoudja, Scaltriti, Maurizio, Drilon, Alexander, Saltz, Leonard, Schram, Alison M, Stadler, Zsofia K, Hyman, David M, Benayed, Ryma, Ladanyi, Marc, Hechtman, Jaclyn F

“…Kinase fusions are rare and poorly characterized in colorectal carcinoma, yet they present unique opportunities for targeted therapy. In this study, we…”
Get full text

Resistance to TRK inhibition mediated by convergent MAPK pathway activation by Cocco, Emiliano, Schram, Alison M., Kulick, Amanda, Misale, Sandra, Won, Helen H., Yaeger, Rona, Razavi, Pedram, Ptashkin, Ryan, Hechtman, Jaclyn F., Toska, Eneda, Cownie, James, Somwar, Romel, Shifman, Sophie, Mattar, Marissa, Selçuklu, S. Duygu, Samoila, Aliaksandra, Guzman, Sean, Tuch, Brian B., Ebata, Kevin, de Stanchina, Elisa, Nagy, Rebecca J., Lanman, Richard B., Houck-Loomis, Brian, Patel, Juber A., Berger, Michael F., Ladanyi, Marc, Hyman, David M., Drilon, Alexander, Scaltriti, Maurizio

“…TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition 1 – 8 . With…”
Get full text

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements by Schram, Alison M, Odintsov, Igor, Espinosa-Cotton, Madelyn, Khodos, Inna, Sisso, Whitney J, Mattar, Marissa S, Lui, Allan J W, Vojnic, Morana, Shameem, Sara H, Chauhan, Thrusha, Torrisi, Jean, Ford, Jim, O'Connor, Marie N, Geuijen, Cecile A W, Schackmann, Ron C J, Lammerts van Bueren, Jeroen J, Wasserman, Ernesto, de Stanchina, Elisa, O'Reilly, Eileen M, Ladanyi, Marc, Drilon, Alexander, Somwar, Romel

“…NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased…”
Get more information

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes by Chang, Jason C, Offin, Michael, Falcon, Christina, Brown, David, Houck-Loomis, Brian R, Meng, Fanli, Rudneva, Vasilisa A, Won, Helen H, Amir, Sharon, Montecalvo, Joseph, Desmeules, Patrice, Kadota, Kyuichi, Adusumilli, Prasad S, Rusch, Valerie W, Teed, Sarah, Sabari, Joshua K, Benayed, Ryma, Nafa, Khedoudja, Borsu, Laetitia, Li, Bob T, Schram, Alison M, Arcila, Maria E, Travis, William D, Ladanyi, Marc, Drilon, Alexander, Rekhtman, Natasha

“…Invasive mucinous adenocarcinoma (IMA) is a unique subtype of lung adenocarcinoma, characterized genomically by frequent mutations or specific gene fusions,…”
Get full text

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies by Murciano-Goroff, Yonina R., Schram, Alison M., Rosen, Ezra Y., Won, Helen, Gong, Yixiao, Noronha, Anne Marie, Janjigian, Yelena Y., Stadler, Zsofia K., Chang, Jason C., Yang, Soo-Ryum, Mandelker, Diana, Offit, Kenneth, Berger, Michael F., Donoghue, Mark T. A., Bandlamudi, Chaitanya, Drilon, Alexander

“…The association between loss of BRCA1/2 and a homologous recombination deficiency phenotype is lineage dependent. In BRCA-associated cancers such as breast,…”
Get full text

Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy by Francis, Jasmine H, Harding, James J, Schram, Alison M, Canestraro, Julia, Haggag-Lindgren, Dianna, Heinemann, Murk, Kriplani, Anuja, Jhaveri, Komal, Voss, Martin H, Bajorin, Dean, Abou-Alfa, Ghassan K, Iyer, Gopa, Drilon, Alexander, Rosenberg, Jonathan, Abramson, David H

“…Fibroblast growth factor receptor (FGFR) 1 to 4 inhibitors are approved by the US Food and Drug Administration and suppress the mitogen-activated protein…”
Get more information

AKT mutant allele-specific activation dictates pharmacologic sensitivities by Shrestha Bhattarai, Tripti, Shamu, Tambudzai, Gorelick, Alexander N., Chang, Matthew T., Chakravarty, Debyani, Gavrila, Elena I., Donoghue, Mark T. A., Gao, JianJong, Patel, Swati, Gao, Sizhi Paul, Reynolds, Margaret H., Phillips, Sarah M., Soumerai, Tara, Abida, Wassim, Hyman, David M., Schram, Alison M., Solit, David B., Smyth, Lillian M., Taylor, Barry S.

“…AKT- a key molecular regulator of PI-3K signaling pathway, is somatically mutated in diverse solid cancer types, and aberrant AKT activation promotes altered…”
Get full text

Precision oncology: Charting a path forward to broader deployment of genomic profiling by Schram, Alison M, Berger, Michael F, Hyman, David M

“…In this Perspective, David Hyman and coauthors discuss clinical research on the application of genomic information in oncology…”
Get full text

Clinical implications of drug‐induced liver injury in early‐phase oncology clinical trials by Mondaca, Sebastian P., Liu, Dazhi, Flynn, Jessica R., Badson, Sandy, Hamaway, Stefan, Gounder, Mrinal M., Khalil, Danny N., Drilon, Alexander E., Li, Bob T., Jhaveri, Komal L., Schram, Alison M., Kargus, Katherine E., Kasler, Mary Kate, Blauvelt, Natalie M., Segal, Neil H., Capanu, Marinela, Callahan, Margaret K., Hyman, David M., Gambarin‐Gelwan, Maya, Harding, James J.

“…Background Data on drug‐induced liver injury (DILI) and acute liver failure (ALF) in modern phase 1 oncology trials are limited, specifically with respect to…”
Get full text

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance by Schram, Alison M., Chang, Matthew T., Jonsson, Philip, Drilon, Alexander

“…Key Points Oncogenic gene fusions are common in patients with solid tumours and occur across a wide spectrum of tumour types Common methods of fusion detection…”
Get full text

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy by Walmsley, Charlotte S., Jonsson, Philip, Cheng, Michael L., McBride, Sean, Kaeser, Christopher, Vargas, Herbert Alberto, Laudone, Vincent, Taylor, Barry S., Kappagantula, Rajya, Baez, Priscilla, Richards, Allison L., Noronha, Anne Marie, Perera, Dilmi, Berger, Michael, Solit, David B., Iacobuzio-Donahue, Christine A., Scher, Howard I., Donoghue, Mark T. A., Abida, Wassim, Schram, Alison M.

“…Reversion mutations that restore wild-type function of the BRCA gene have been described as a key mechanism of resistance to Poly(ADP-ribose) polymerase (PARP)…”
Get full text

Marked hyperferritinemia does not predict for HLH in the adult population by Schram, Alison M., Campigotto, Federico, Mullally, Ann, Fogerty, Annemarie, Massarotti, Elena, Neuberg, Donna, Berliner, Nancy

“…Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of uncontrolled immune activation that has gained increasing attention during the last decade. The…”
Get full text

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden by Benayed, Ryma, Offin, Michael, Mullaney, Kerry, Sukhadia, Purvil, Rios, Kelly, Desmeules, Patrice, Ptashkin, Ryan, Won, Helen, Chang, Jason, Halpenny, Darragh, Schram, Alison M, Rudin, Charles M, Hyman, David M, Arcila, Maria E, Berger, Michael F, Zehir, Ahmet, Kris, Mark G, Drilon, Alexander, Ladanyi, Marc

“…Targeted next-generation sequencing of DNA has become more widely used in the management of patients with lung adenocarcinoma; however, no clear mitogenic…”
Get full text

Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years by Schram, Alison M., Comstock, Paige, Campo, Meghan, Gorovets, Daniel, Mullally, Ann, Bodio, Kelly, Arnason, Jon, Berliner, Nancy

“…Summary Haemophagocytic lymphohistiocytosis (HLH) is a syndrome of uncontrolled immune activation that has gained increasing attention over the past decade…”
Get full text

Genome doubling shapes the evolution and prognosis of advanced cancers by Bielski, Craig M., Zehir, Ahmet, Penson, Alexander V., Donoghue, Mark T. A., Chatila, Walid, Armenia, Joshua, Chang, Matthew T., Schram, Alison M., Jonsson, Philip, Bandlamudi, Chaitanya, Razavi, Pedram, Iyer, Gopa, Robson, Mark E., Stadler, Zsofia K., Schultz, Nikolaus, Baselga, Jose, Solit, David B., Hyman, David M., Berger, Michael F., Taylor, Barry S.

“…Ploidy abnormalities are a hallmark of cancer, but their impact on the evolution and outcomes of cancers is unknown. Here, we identified whole-genome doubling…”
Get full text

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology by Tao, Jessica J, Schram, Alison M, Hyman, David M

“…Understanding a tumor's detailed molecular profile has become increasingly necessary to deliver the standard of care for patients with advanced cancer…”
Get full text

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations by Rosen, Ezra Y, Goldman, Debra A, Hechtman, Jaclyn F, Benayed, Ryma, Schram, Alison M, Cocco, Emiliano, Shifman, Sophie, Gong, Yixiao, Kundra, Ritika, Solomon, James P, Bardelli, Alberto, Scaltriti, Maurizio, Drilon, Alexander, Iasonos, Alexia, Taylor, Barry S, Hyman, David M

“…TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known,…”
Get full text

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours by Schram, Alison M., Gandhi, Leena, Mita, Monica M., Damstrup, Lars, Campana, Frank, Hidalgo, Manuel, Grande, Enrique, Hyman, David M., Heist, Rebecca S.

“…Background This phase Ib study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of pimasertib…”
Get full text

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials by Desai, Aakash, Gainor, Justin F., Hegde, Aparna, Schram, Alison M., Curigliano, Giuseppe, Pal, Sumanta, Liu, Stephen V., Halmos, Balazs, Groisberg, Roman, Grande, Enrique, Dragovich, Tomislav, Matrana, Marc, Agarwal, Neeraj, Chawla, Sant, Kato, Shumei, Morgan, Gilberto, Kasi, Pashtoon M., Solomon, Benjamin, Loong, Herbert H., Park, Haeseong, Choueiri, Toni K., Subbiah, Ishwaria M., Pemmaraju, Naveen, Subbiah, Vivek

“…Emerging efficacy data have led to the emergency use authorization or approval of COVID-19 vaccines in several countries worldwide. Most trials of COVID-19…”
Get full text